Nina Vasavada, Rajiv Agarwal Kidney International

Slides:

Advertisements

Similar presentations

A.M. Thompson, T.G. Pickering Kidney International

Advertisements

Nina Vasavada, Rajiv Agarwal Kidney International

Plasma sodium and hypertension

Combination therapy with ACE inhibitors and angiotensin II receptor blockers in chronic renal disease: New therapeutic world beyond blood pressure reduction

Giovanni Davogustto, MD, Thomas J. Wang, MD, Deepak K. Gupta, MD

Anemia management in chronic kidney disease

Volume 90, Issue 5, Pages (November 2016)

Rajiv Agarwal, John W. Kusek, Maria K. Pappas Kidney International

Volume 85, Issue 2, Pages (January 2014)

Prehypertension and chronic kidney disease: the ox or the plow?

Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007 Joanna M. Smith, Susan A. Mott,

Volume 80, Issue 10, Pages (November 2011)

John P. Middleton, Patrick H. Pun Kidney International

Volume 88, Issue 2, Pages (August 2015)

The myogenic response in uremic hypertension

Is there a pharmacologic basis for combination renin axis blockade?

Volume 90, Issue 3, Pages (September 2016)

The progression of chronic kidney disease: A 10-year population-based study of the effects of gender and age B.O. Eriksen, O.C. Ingebretsen Kidney International

Nosratola D. Vaziri, Kaihui Liang, Yaoxian Ding Kidney International

Kidney immune cell infiltration and oxidative stress contribute to prenatally programmed hypertension Tyrus Stewart, Flavia F. Jung, Jennifer Manning,

Volume 69, Issue 2, Pages (January 2006)

Prediction of hypertension in chronic hemodialysis patients

Anemia as a risk factor for chronic kidney disease

Urinary aquaporin-2 in healthy humans and patients with liver cirrhosis and chronic heart failure during baseline conditions and after acute water load

Proinflammatory effects of iron sucrose in chronic kidney disease

Volume 74, Issue 3, Pages (August 2008)

Volume 80, Issue 10, Pages (November 2011)

N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment Martina Franz, Wolfgang Woloszczuk, Walter.

Volume 70, Issue 11, Pages (December 2006)

The epidemiology of chronic kidney disease

Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease S. Bianchi, R. Bigazzi, V.M. Campese

Volume 71, Issue 6, Pages (March 2007)

Volume 68, Issue 6, Pages (December 2005)

Volume 68, Issue 1, Pages (July 2005)

Volume 60, Issue 4, Pages (October 2001)

Volume 73, Issue 12, Pages (June 2008)

Volume 85, Issue 3, Pages (March 2014)

Volume 81, Issue 6, Pages (March 2012)

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Proteinuria and hypertensive nephrosclerosis in African Americans

Methods for guideline development

The kidney, a cardiovascular risk marker, and a new target for therapy

Counteracting progression of renal disease: A look into the future

The global challenge of chronic kidney disease

Nina Vasavada, Chandan Saha, Rajiv Agarwal Kidney International

Volume 82, Issue 9, Pages (November 2012)

Volume 64, Issue 2, Pages (August 2003)

Volume 67, Issue 1, Pages (January 2005)

Volume 71, Issue 9, Pages (May 2007)

Volume 63, Issue 2, Pages (February 2003)

Volume 76, Issue 1, Pages (July 2009)

The course of the remnant kidney model in mice

Organ transplantation goes to the movies

Volume 69, Issue 1, Pages (January 2006)

Blood lead and chronic kidney disease in the general United States population: Results from NHANES III Paul Muntner, Jiang He, Suma Vupputuri, Josef.

Pablo A. Ureña Torres, Marc De Broe Kidney International

Salt sensitivity in genetically hypertensive rats of the Lyon strain

Is it the low-protein diet or simply the salt restriction?

Volume 75, Issue 1, Pages (January 2009)

The hypothesis that abnormal BH4 metabolism impairs kidney function

Is complement a target for therapy in renal disease?

Volume 65, Issue 4, Pages (April 2004)

Volume 58, Issue 2, Pages (August 2000)

In chronic kidney disease staging the use of the chronicity criterion affects prognosis and the rate of progression B.O. Eriksen, O.C. Ingebretsen Kidney.

Volume 74, Issue 10, Pages (November 2008)

Kidney and hypertension

Quantitative estimation of renal blood flow by power Doppler ultrasonography in renovascular hypertensive dogs Tetsumasa Miyajima, Hiroshi Yokoyama,

Sugar-sweetened beverages and chronic disease

Presentation transcript:

Role of excess volume in the pathophysiology of hypertension in chronic kidney disease Nina Vasavada, Rajiv Agarwal Kidney International Volume 64, Issue 5, Pages 1772-1779 (November 2003) DOI: 10.1046/j.1523-1755.2003.00273.x Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 1 Brain natriuretic peptide (BNP) responses after single (A) and multiple (B) doses of torsemide and furosemide therapy for each subject. Closed triangles represent treatment with torsemide; open triangles represent treatment with furosemide. Box plots represent the median, 10th, 25th, 75th, and 90th percentiles of each data set. Ln is natural log. Kidney International 2003 64, 1772-1779DOI: (10.1046/j.1523-1755.2003.00273.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 2 Plasma renin activity (PRA) (A) and plasma aldosterone (PA) responses after multiple doses of torsemide and furosemide therapy for each subject. Closed triangles represent treatment with torsemide; open triangles represent treatment with furosemide. Box plots represent the median, 10th, 25th, 75th, and 90th percentiles of each data set. Kidney International 2003 64, 1772-1779DOI: (10.1046/j.1523-1755.2003.00273.x) Copyright © 2003 International Society of Nephrology Terms and Conditions

Figure 3 Time course of biophysical and hormonal measurements of volume status during multiple dose study.*P < 0.05 in comparison with baseline measurements by analysis of variance (ANOVA) for systolic blood pressure and Tukey honest significant test for other parameters. Multivariate ANOVA for all comparisons were significant. Kidney International 2003 64, 1772-1779DOI: (10.1046/j.1523-1755.2003.00273.x) Copyright © 2003 International Society of Nephrology Terms and Conditions